Efficacy and Safety of Eplivanserin 5mg/Day on Sleep Maintenance Insomnia (EPOCH)

Efficacy and Safety of Eplivanserin 5mg/Day on Sleep Maintenance Insomnia: A 6 Week, Multicenter, Randomized, Double -Blind, Placebo-controlled Study

The aim of the study is to confirm the efficacy of eplivanserin 5mg/day on sleep maintenance of patients with primary insomnia using night polysomnography recordings over a 6-week treatment period corresponding to a stabilization of improvement of sleep.

Study Overview

• Status: Completed
• Conditions: Insomnia; Sleep Initiation and Maintenance Disorders
• Intervention / Treatment: Drug: placebo; Drug: eplivanserin (SR46349)

• Study Type: Interventional
• Enrollment (Actual): 608
• Phase: Phase 3

Contacts and Locations

Study Locations

• Australia
  • New South Wales
    • Macquarie Park, New South Wales, Australia
      • Sanofi-Aventis
• Canada
  • Laval, Canada
    • Sanofi-Aventis
• United States
  • New York
    • Bridgewater, New York, United States, 08807
      • Sanofi-Aventis

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Diagnosis of primary insomnia based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for at least one month preceding the study visit.

• Disturbance of sleep maintenance:

  • Based on patient' s information:

    • Patient has spent at least 6.5 hours and not more than 9.0 hours, in bed, each night, over the preceding two weeks,
    • Patient must complain of at least one hour of wakefulness after sleep onset for at least 3 nights per week over the preceding month,
    • Patient must report impact on daytime functioning associated with sleep maintenance insomnia

Inclusion will be based on the nocturnal polysomnography (NPSG) recordings performed at the sleep laboratory during the two screening nights.

Exclusion Criteria:

• Females who are lactating or who are pregnant, or of childbearing potential not using an acceptable form of contraception
• Patients presenting with acute or chronic pain resulting in insomnia
• Patients with current psychiatric disturbances
• Body mass index > 32
• Evidence of any clinically significant, severe or unstable, acute or chronically progressive medical or surgical disorder, or any condition that may interfere with the absorption, metabolism, distribution or excretion of the study drug, or may affect patient safety
• Clinically significant and abnormal electrocardiogram (ECG) (including QTc B > 500ms),
• A positive test for hepatitis B (hepatitis B surface [HBs] antigens) or C (hepatitis C virus [HCV] antibodies)
• Positive qualitative urine drug screen at screening
• Consumption of xanthine-containing beverages (i.e. tea, coffee, or cola) comprising usually more than 5 cups or glasses per day
• Use of any over-the-counter or prescription sleep medication, or of any substance with psychotropic effects or properties known to affect sleep/wake, within one week or five half-lives (whichever is longer), prior to screening
• Night shift workers, and individuals who nap 3 or more times per week over the preceding month

• Based on medical history and/or NPSG:

  • primary hypersomnia
  • narcolepsy
  • breathing-related sleep disorder (apnea-hypopnea index > 10/hour of sleep)
  • circadian rhythm sleep disorder
  • parasomnia (e.g. somnambulism)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: 2	Drug: placebo; oral administration
Experimental: 1; 5 mg/day	Drug: eplivanserin (SR46349); oral administration

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Change from baseline of night polysomnography Wake Time After Sleep Onset (PSG WASO)	week 6

Secondary Outcome Measures

Outcome Measure	Time Frame
Change from baseline in general productivity domain of the FOSQ (Functional Outcome of Sleep Questionnaire)	week 6
Change from baseline in patient reported wake after sleep onset (pr-WASO)	week 6

Collaborators and Investigators

• Sponsor: Sanofi

Study record dates

Study Major Dates

• Study Start: February 1, 2006
• Primary Completion (Actual): August 1, 2007
• Study Completion (Actual): August 1, 2007

Study Registration Dates

• First Submitted: March 28, 2006
• First Submitted That Met QC Criteria: March 28, 2006
• First Posted (Estimate): March 29, 2006

Study Record Updates

• Last Update Posted (Estimate): November 30, 2010
• Last Update Submitted That Met QC Criteria: November 29, 2010
• Last Verified: November 1, 2010

More Information

Terms related to this study

• Keywords: Primary Insomnia; Sleep Maintenance Insomnia; Awakening
• Additional Relevant MeSH Terms: Mental Disorders; Nervous System Diseases; Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders; Sleep Initiation and Maintenance Disorders; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Fibrinolytic Agents; Fibrin Modulating Agents; Platelet Aggregation Inhibitors; Serotonin Agents; Serotonin Antagonists; SR 46349B
• Other Study ID Numbers: EFC6220